Introduction {#S1}
============

The neurovascular unit (NVU) is a functional complex critical to the stability of the CNS microenvironment and is composed of endothelial cells (ECs), glial cells, pericytes (PCs), neurons, and the extracellular matrix (ECM). Communication between the individual NVU components is key for its correct function. The blood-brain barrier (BBB) is considered the core structure of the NVU ([@B152]). It is established by tightly sealed ECs located at the luminal surface of the brain's vascular tree ([@B180]). The presence of cell surface proteins, ion channels, efflux pumps, enzymes, specific receptors, and transporters on pericytes (PCs), vascular smooth muscle cells (VSMCs), and ECs maintain BBB integrity ([@B180]) and allow bidirectional regulation of substances by transcellular or paracellular transport ([@B73]; [@B213]).

Under normal conditions, ECs in the CNS microvasculature have fewer endocytic vesicles than those in the endothelia of the peripheral capillaries and only ensure the supply of basic nutrients, including oxygen and glucose, to the neurons ([@B136]). Thus, decreased transcytosis across the BBB restricts permeability and impedes the delivery of therapeutic agents, which is of great importance for restoring CNS homeostasis under pathological conditions ([@B113]). Additionally, ECs also bidirectionally communicate with surrounding cells to maintain the dynamic nature of the BBB.

Blood-brain barrier dysfunction is a pathophysiological hallmark in the pathogenesis of multiple CNS diseases ([@B39]). Extensive evidence implicates it in cerebrovascular, neurodegenerative, and neuroinflammatory diseases. Here, we first illustrate the physiological structure of the BBB and then discuss the development of junctional complex perturbations in pathological conditions, including cerebrovascular disease and neurodegenerative disorders. Finally, we summarize recent advancements in therapeutics targeting brain-barrier function. We emphasize the significance of the BBB in neurological disorders and put forward crucial questions to be answered in the future.

The Blood-Brain Barrier Establishment {#S2}
=====================================

Angiogenesis and Barriergenesis {#S2.SS1}
-------------------------------

Prior to BBB development, neuroectodermal neural progenitor cells secrete vascular endothelial growth factor (VEGF) to guide angioblasts from the perineural vascular plexus across the neuroectoderm to initiate angiogenesis ([@B139]; [@B131]). Meanwhile, neural progenitor cells also release Wnt ligands and activate the Wnt/β-catenin signaling pathway, which induces expression of genes indispensable for angiogenesis and BBB barriergenesis ([@B175]). Orphan G-protein-coupled receptor 124 (Gpr124), a coactivator of the Wnt/β-catenin pathway, also impacts angiogenesis ([@B219]). During angiogenesis, nascent vascular ECs secrete platelet-derived growth factor-BB (PDGF-BB) and recruit PCs via the PDGF-receptor (PDGFR) ([@B178], [@B180]). PCs work synergistically with vascular ECs, deliver basement membrane (BM) proteins, and regulate integration of the BBB through interaction with the astrocyte end-feet that encircle vessels ([@B43]; [@B8]). The Sonic hedgehog (Hh) signaling pathway is crucial for EC polarity. Sonic hedgehog (SHH) released by astrocytes combines with Hh expressed by ECs to promote the expressions of tight junction (TJ) proteins and junctional adhesion molecules (JAMs). The SHH signaling pathway also suppresses the expression of proinflammatory factors and intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting infiltration of leukocytes ([@B5]; [@B106]; [@B180]).

Anatomical Structure {#S2.SS2}
--------------------

Endothelial cells in the CNS are distinct from those other tissues due to the following properties: possession of continuous intercellular TJs, lack of fenestration and pinocytosis, and low expression of leukocyte adhesion molecules ([@B131]; [@B106]). The BBB formed by the ECs is a dynamic but impassable wall, restricting the exchange of paracellular or transcellular substances and abrogating the infiltration of leukocytes.

Tight junction proteins, JAMs, adherens junctions (AJs), and gap junctions are responsible for restricting substance movement by prohibiting the paracellular pathway ([@B152]). On the other hand, enzymes and influx/efflux pumps maintain the dynamic nature of the barrier, limiting non-specific transport while also allowing specific transport ([@B152]).

Junctional molecules at the BBB are divided into four categories: TJ (with TJ proteins and TJ-associated proteins), AJ, JAM, and gap junctions ([@B35]; [@B185]; [@B180]). They communicate with the cellular actin cytoskeleton via membrane-associated guanylate kinases (MAGUK), such as zonula occludens-1 (ZO-1), ZO-2, and ZO-3 ([@B17]; [@B221]). TJ proteins are closest to the apical membrane and seal the BBB, thus acting as potential therapeutic targets. On the other hand, AJs, composed mainly of VE-cadherin and platelet endothelial cell adhesion molecule-1 (PECAM-1), are closest to the basolateral membrane ([@B180]). JAMs consist of proteins, including JAM-A, JAM-B, and JAM-C, and endothelial cell adhesion molecules (ESAMs), and regulate transmigration of leukocytes across the BBB ([@B63]; [@B180]). Gap junction proteins include connexin-37, connexin-40, and connexin-43 and act as a sort of "hemichannel" to facilitate communication between adjacent ECs ([@B180]).

Claudin-1 is a non-specific claudin in vessels, overexpression of which has been reported to reduce the disease burden in the chronic phase of a mouse model of multiple sclerosis (MS) ([@B137]). However, it has also been shown that claudin-1 overexpression decreased the level of claudin-5 and induced a proinflammatory phenotype in ECs in chronic stroke ([@B168]). This suggests that claudin-1 overexpression compensated for BBB dysfunction only in the acute phase of injury. In addition to this, genetic polymorphisms in claudin-1 have been shown to contribute to small vessel vascular dementia ([@B173]). Claudin-3 is involved in BBB induction and maintenance through signaling via the Wnt/β-catenin pathway ([@B138]), while claudin-5 restricts the entrance of molecules up to 800 Da ([@B127]). Genetically modified mice lacking claudin-5 demonstrated leakage of intravascular tracers less than 800 Da in size despite having an intact BBB; 95% of pharmaceuticals are within this size range, implying that modulation of claudin-5 could be a potential target for drug delivery ([@B187]; [@B73]). [@B29] found that mice lacking claudin-12 still maintained an intact BBB as claudin-12 appears to be more important for cardiovascular functions ([@B29]). It has also been shown to be involved in paracellular Ca^2+^ permeation in enterocytes ([@B153]). To date, the exact function of claudin-12 in the CNS remains unknown and needs further investigation. Conversely, occludin is specifically expressed by the cells of the BBB rather than in non-neuronal tissues ([@B45]). Consequently, occludin knock-out mice show morphologically normal TJs despite development of brain calcification ([@B60]). LSR/angulin-1 are significant for maintenance of BBB characteristics, so loss of LSR results in leakage of small molecules ([@B84]; [@B171]).

Cadherins and PECAM-1 are examples of proteins that make up AJs. VE-cadherin is important for AJ assembly and BBB regulation ([@B110]). In conditions of oxygen-glucose deprivation (OGD), VE-cadherin internalization induces BBB hyperpermeability via the RhoA/ROCK2 pathway ([@B30]). VE-cadherin phosphorylation under pathological conditions results in uncoupling of ECs and increased vascular permeability; thus, it may also serve as a novel target in moderating BBB dysfunction ([@B110]).

ZO-1 is indispensable for assembly of junction complexes between ECs. Both downregulation and phosphorylation of ZO-1 results in impaired BBB integrity ([@B31]). Connexin is a hemichannel protein expressed by ECs. It opens at low extracellular concentrations of Ca^2+^ or under OGD and perturbs transport across the BBB ([@B182]). Knockout of Connexin-43/30 in astrocytes (ACs) results in end-feet edema and loss of aquaporin-4 (AQP-4) expression ([@B55]).

JAM-A is a unique protein in that it has diverging functions under physiological and pathological conditions. During homeostasis, it moderates paracellular transport, and during inflammatory conditions, it is redistributed to the apical surface of ECs and serves as an adhesion molecule, regulating leukocyte migration ([@B174]). It has been shown that JAM-A antagonists can modulate leukocyte infiltration in ischemia/reperfusion (I/R) injury, thereby making JAM-A a potential therapeutic target ([@B169]). Mice void of JAM-B show extensive vacuolation in the brain parenchyma along with neurodegeneration ([@B158]). Moreover, bi-allelic JAM2 variants result in brain calcification, which could be attributed to dysfunction of solute transport ([@B158]).

ECs attach to the BM via the binding of integrins to ECM ligands and stimulate multiple pathways, including growth factors, growth factor receptors, or transactivation of growth factor receptors. They have Na^+^-K^+^-Cl^--^ cotransporters and Na^+^/H^+^ exchangers at the luminal side and Na^+^/K^+^-ATPases at the abluminal side ([@B11]).

Anatomically, PCs share a common BM and interdigitate with ECs, forming peg-and-socket contacts in regions lacking a BM via *N*-cadherin and connexins ([@B207]); they have multiple functions, including adjusting vascular stability ([@B7]), managing capillary diameter to regulate cerebral blood flow (CBF) ([@B70]), and phagocytosing toxins ([@B150]) to ensure BBB stability ([@B207]). PC coverage of ECs is mediated through release of PDGF-β and activation of PDGFR by ECs. *Pdgfrb^--/--^* mice manifest with a low pericyte coverage rate, aberrant capillary dilation, and increased BBB permeability ([@B46]).

Astrocytes are the most abundant glial cells in the CNS ([@B115]). Their functions include balancing the extracellular potassium concentration, regulation of neurotransmitter delivery, excretion of growth factors, and metabolic support to neurons ([@B64]). Secretion of SHH, retinoic acid (RA) and angiopoietin-1 (Ang-1) by ACs is crucial to sustain EC impermeability ([@B5]; [@B68]). In turn, ECs can regulate differentiation of ACs via production of bone morphogenetic proteins (BMPs) and activating the Smad signaling pathway in progenitors ([@B85]).

ECs, ACs, and PCs all secrete ECM and form the BM. Multiple structural proteins (for instance, collagen type 4 and laminin), cell adhesion molecules, and extracellular matrix proteins make up the BM ([@B27]). The BM interacts with surrounding cells to control vascularization and coordinate signaling between components of the NVU ([@B131]).

Transport System {#S2.SS3}
----------------

The BBB transport system can be classified into the following categories: carrier-mediated transport (CMT), receptor-mediated transport (RMT), efflux transporters, and ion transporters ([@B180]) ([Figure 1](#F1){ref-type="fig"}). Corresponding transporters to these can also be found on PCs. Each transport system is discussed in turn, and then, we elaborate several common transporters involved in undermentioned diseases.

![Endothelial cells, pericytes, the extracellular matrix, glial cells, and neurons are all basic components of the neurovascular unit. The blood-brain barrier (BBB) is composed of specialized endothelial cells. The transport system of the BBB includes carrier-mediated transport (CMT), receptor-mediated transport (RMT), efflux transporters, and ion transport. Gases, such as oxygen and carbon dioxide, and small lipophilic molecules less than 400 Da in size can freely diffuse across the BBB.](fnins-14-00764-g001){#F1}

Carrier-mediated transport is responsible for transport of solutes, including carbohydrates, amino acids, and so on. Glucose transporter type 1 (GLUT1) is critically important in providing the CNS with energy. Therefore, GLUT1 dysfunction contributes to a variety of CNS diseases, termed GLUT1-deficiency syndromes (Glut1-DS), such as drug-resistant epileptic seizures, psychomotor retardation, ataxia, and microcephaly ([@B62]; [@B97]). It also plays a role in AD pathogenesis as discussed below.

The main efflux pumps are the ATP-binding cassette (ABC) transporters. ABC transporters utilize ATP and pump out xenobiotics or endogenous metabolites to maintain EC homeostasis ([@B35]; [@B49]; [@B123]). ABCB1 (also known as *P*-glycoprotein, *P*-gp), ABCG2, and ABCC1 are all efflux transporters involved in the elimination of amyloid-β (Aβ), and so inhibition of these influences the Aβ level in the brain ([@B162]). In addition to AD, *P*-gp is involved in pathogenesis of stroke, epilepsy, and MS through upregulation or downregulation of expression influencing the inflammatory response ([@B81]).

Low-density lipoprotein receptor--related protein (LRP) is a lipoprotein receptor. It efficiently mediates clearance of Aβ, particularly Aβ42, via an LRP1/apolipoprotein E (APOE) isoform-specific mechanism ([@B117]). Both *P*-gp and LRP are regulated by phosphatidylinositol-binding clathrin assembly protein (PICALM) and PICALM deficiency diminishes transcytosis and clearance of Aβ ([@B219]; [@B177]). Conversely, the receptor for advanced glycation end products (RAGE) interacts with Aβ and mediates its transport across the BBB, thus inducing the release of proinflammatory cytokines ([@B50]).

Na^+^-K^+^-ATPases, Na^+^-K^+^-2Cl^--^ cotransporters (NKCC1), Na^+^-H^+^ exchangers (sodium pump), and Na^+^-Ca^2+^ exchangers are vital transporters for ionic equilibrium. Na^+^-K^+^-ATPase and NKCC1 function to maintain balance of sodium-potassium concentrations in the brain to guarantee stable physiological activity of neurons. The Na^+^-H^+^ exchanger is key for regulating normal pH of ECs, and the Na^+^-Ca^2+^ exchanger maintains a low level of intracellular Ca^2+^ in ECs ([@B180]). Dysfunction of ion transporters contributes to ionic imbalance, resulting in release of inflammatory mediators.

Cerebrovascular Disease {#S3}
=======================

Acute Ischemic Stroke {#S3.SS1}
---------------------

Acute ischemic stroke (AIS) is primarily caused by transient or permanent reduction in CBF induced by an embolus or thrombosis blocking regional arteries (except in cases of lacunar infarction) ([@B53]); it induces a series of pathological events, including BBB disruption, vasogenic edema, hemorrhagic transformation (HT), and neuronal injury ([@B164]). Intravenous tissue-type plasminogen activator (tPA) is an effective treatment for AIS if administered within a specific therapeutic time window ([@B140]). However, BBB impairment restricts the application of this thrombolytic treatment; tPA passes through the impaired BBB and activates matrix metalloproteinase-9 (MMP-9) within the parenchyma, inducing ECM degradation and further altering BBB permeability. Consequently, BBB disruption aggravates cerebral edema, elevates risk of fatal HT, and intensifies the neuroinflammatory reaction after AIS ([@B94]; [@B33]). Therefore, BBB disruption is critical in AIS and contributes to subsequent brain damage.

Stroke is composed of two successive phases, ischemia and reperfusion, based on the paracellular penetrative state ([@B154]). In the ischemic phase, CBF is reduced, resulting in a deficient supply of glucose and oxygen ([@B154]). Glucose and oxygen are essential to maintain an adequate supply of adenosine triphosphate (ATP) to guarantee physiological cellular function and maintain normal ion gradients ([@B1]). Following the onset of ischemia, oxidative phosphorylation is discontinued, followed by an ATP shortage ([@B74]). EC ion transporters are unable to function with inactivation of Na^+^-K^+^-ATPases and Ca^2+^-ATPases due to lack of energy. Increased activity of other ion transporters, such as Na^+^-H^+^ exchangers, NKCC1, and the calcium-activated potassium channel, KCa3.1, elevates intracellular Na^+^ levels and causes cytotoxic edema ([@B94]; [@B213]). Na^+^ accumulation also leads to membrane depolarization and Na^+^-Ca^2+^ exchanger dysfunction, resulting in Ca^2+^ efflux and calcium overload ([@B1]). This promotes the release of excitatory neurotransmitters and reactive oxygen species (ROS), which induce inflammatory cascades and destroy the BBB ([@B89]; [@B2]). KCa3.1 blockade is capable of reversing cerebral edema within 3 h of AIS ([@B32]). Similarly, inhibition of NKCC1 can alleviate brain edema and neurological impairment ([@B44]). Sodium-dependent glucose transporters (SGLTs) and GLUT1 both play a role in glucose transportation under pathological and physiological conditions, respectively. The function of SGLTs are dependent on the NKCC1-mediated sodium gradient, which contributes to sodium accumulation in ECs during stroke. Inhibition of SGLTs has been shown to reduce edema and improve poststroke outcome ([@B193]). Interestingly, another study has shown that SGLTs are also present in neurons but not BBB ECs under physiological conditions ([@B217]; [@B135]). In any event, BBB ion transporters provide a hopeful therapeutic target.

In the reperfusion phase, CBF starts to recover, which is beneficial for neuronal survival but increases the risk of HT. BBB injury is a core pathophysiological mechanism in reperfusion damage ([@B193]), and increased BBB permeability further increases HT risk ([@B154]). BBB dysfunction can be characterized into three stages: stage 1 includes the effects of oxidative stress on the BBB and associated ECM degeneration, whereas stages 2 and 3 are associated with vasogenic edema and angiogenesis. Alterations in BBB TJs during phase 1 induce the changes seen in stages 2 and 3 ([@B77]; [@B94]). Activation of proteinases, such as MMPs, and tPA, are the most important contributors to BBB breakdown and are stimulated by either hypoxia-inducible factor-1α (HIF-1α)-dependent mechanisms or cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin 1β (IL-1β) ([@B216]). MMPs, particularly MMP-2 and MMP-9 have been shown to degrade TJ proteins ([@B216]; [@B114]). MMP-9, derived from neutrophils, degrades claudin-5 and the BM following ischemia, resulting in brain edema, neurological deficits and increased HT risk ([@B120]). In experimental stroke mice, elevated levels of α2-antiplasmin enhanced the expression of MMP-9, exacerbating BBB breakdown and ischemic injury ([@B166]). In addition to MMPs, caveolin-1 mediates the translocation and downregulation of claudin-5, exacerbating BBB leakage ([@B112]). Furthermore, exudation of inflammatory cells also aggravates BBB breakdown ([@B164]), accompanied by reduced expression of occluding ([@B112]), ZO-1 ([@B92]), and VE-cadherin ([@B197]; [@B203]). For example, microglia secrete cytokines to stimulate upregulation of intercellular adhesion molecule-1 (ICAM-1), *P*-selectin and *E*-selectin on the surface of ECs, mediating the infiltration of neutrophils ([@B201]). Rho kinase (RhoK) mediates the phosphorylation of occludin and claudin-5, increasing BBB permeability ([@B214]). C-C motif ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1) elevates expression of caveolin-1, resulting in phosphorylation of occludin and ZO-1, and thus, exacerbating BBB leakage. In summary, ischemia and hypoxia induce BBB dysfunction, which then facilitates inflammatory cascades that further induce decompose BBB dysfunction. Thus, the BBB is not only influenced by AIS but also contributes to AIS pathology ([Figure 2](#F2){ref-type="fig"}).

![Schematic diagram of blood-brain barrier alterations in acute ischemic stroke. Reduced levels of glucose and oxygen result in dysfunction of EC ion transporters, inducing calcium overload and triggering inflammatory cascades. These inflammatory cascades further degrade tight junctions, thus aggravating brain edema and increasing infarct size.](fnins-14-00764-g002){#F2}

In recent years, research has focused on exploring advanced therapies to alleviate BBB damage. Chemokine receptor type 5 (CCR5) stimulates regulatory T cells (Tregs) strengthens BBB immunoregulatory function and ameliorates inflammatory cascades, thus representing a potential treatment target ([@B109]). Circular RNA DLGAP4 (circDLGAP4) can bind to miR-143, maintaining BBB integrity and diminishing infarct volume in AIS patients ([@B13]). miR-98 protects EC stability and strengthens BBB integrity through modifying activation of small Rho GTPases, rearranging the actin cytoskeleton, and redistributing TJ proteins. It also limits the recruitment of inflammatory cells by reducing expression of the proinflammatory cytokines, CCL2 and CCL5 ([@B19]). Transplantation of mesenchymal stem cells (MSCs) is a prominent research focus as they can promote neurogenesis and angiogenesis in the BBB ([@B40]). Integrin α5β1 mediates leukocyte infiltration and subsequent BBB dysfunction; the integrin α5β1 inhibitor, ATN-161, can preserve claudin-5 and collagen-IV expression and reduce MMP-9 transcription, thus protecting BBB integrity ([@B54]). Perlecan, a major heparan sulfate proteoglycan component of the BM, can maintain and repair the injured BBB by reinforcing the BM ([@B128]). Furthermore, release of microvesicles by ECs can upregulate ZO-1 and claudin-5 expression, thereby ameliorating BBB disruption and reducing infarct volume ([@B133]). Cystatin C is also capable of reducing the expression of caveolin-1, restricting the activity of MMP-9 and elevating occludin expression in mice that have undergone middle cerebral artery occlusion (MCAO) ([@B215]). It has been shown that deficiency of vitamin D hormone (VDH) reduces occludin and claudin-5 expression and correlates with poor prognosis in stroke ([@B14]; [@B176]). Therefore, sufficient supplementation of VDH appears to be advantageous to maintaining BBB integrity ([@B156]). Nanoparticles are an efficient method for transporting pharmacological compounds across the BBB. For instance, [@B16] designed edaravone-loaded ceria nanoparticles that cleared ROS produced by AIS and effectively protected the BBB with minimal side-effects. Combination treatment with recombinant tissue plasminogen activator (rt-PA) and minocycline or rt-PA and cilostazol has been shown to protect TJ proteins from secondary degradation following thrombolysis ([@B86]; [@B56]). Moreover, type 5 NADPH oxidase (NOX5) induces ROS; thus, applying a NOX5 inhibitor together with reperfusion treatment (thrombolysis or thrombectomy) has been shown to reduce ROS generation and ameliorate BBB injury ([@B28]). CO-releasing molecule (CORM)-3 decreases the level of TNF-α, and IL-1β, upregulates expression of PDGFR-β and ZO-1 and inhibits activity of MMP-9, thus alleviating BBB disruption in transient-MCAO mice ([@B200]).

Intracerebral Hemorrhage {#S3.SS2}
------------------------

Intracerebral hemorrhage (ICH) is a leakage of blood components from damaged vessels and into the brain parenchyma ([@B144]). The pathophysiology of ICH includes two phases; hematomas induce the initial mechanical compression damage, which leads to mitochondrial dysfunction and membrane depolarization. Cells affected by this damage induce secondary injury, which is characterized by excitotoxicity and oxidative stress caused by cellular dysfunction and the presence of blood components ([@B144]; [@B161]). Perihematomal edema (PHE) is evident in both stages although the relevant pathogenesis is different.

PHE develops immediately after ICH onset ([@B194]), which leads to rapid deterioration in the patient and subsequent poor prognosis ([@B119]). It can be divided into three phases: phase 1 includes osmotic edema caused by the initial damage, and phases 2 and 3 are characterized by vasogenic edema resulting from secondary damage ([@B188]).

The osmotic edema phase, phase 1, occurs within the first hours of ICH onset and is composed of clot retraction and cytotoxic edema ([@B212]). Clot retraction occurs due to a secondary coagulation cascade, which extrudes serum proteins and prompts interstitial accumulation of ions and water. The cytotoxic edema can mainly be ascribed to dysfunction of cellular ionic pumps (such as Na^+^-K^+^-ATPase and NKCC1), resulting in sodium influx and edema formation ([@B188]). Phase 2, including the first 2 days in ICH, encompasses a further coagulation cascade and stimulation of thrombin. Thrombin combines with protease-activated receptor-4 (PAR-4) and stimulates microglia ([@B22]), which then release cytokines including TNF and IL-1β; TNF has been shown to be a pivotal factor in downregulation of the TJ proteins ([@B212]; [@B9]). However, thrombin also induces PAR-1 and phosphorylates myosin light chain (MLC) in ECs, strengthening their contractility and increasing intercellular gaps ([@B165]; [@B188]). Moreover, thrombin facilitates leukocyte infiltration, followed by ROS production and increased ICAM expression in ECs, which further enhances leukocyte exudation ([@B20]). The complement cascade also contributes to PHE development. Recruitment of chemokines results in generation of membrane attack complexes (MACs) that promote dissolution of red blood cells (RBCs) and edema induced by blood components ([@B22]; [@B188]). Phase 3, following from phase 2, also contributes to BBB disruption. RBCs are degraded into hemoglobin (Hb) and iron by MACs. Hb activates the Toll-like receptor-2/4 (TLR2/TLR4) heterodimer, which promotes oxidative stress and mediates further BBB disruption ([@B188]). MMP-9, as a downstream factor activated by ROS, is key to iron-mediated edema. As previously discussed, it degrades TJ proteins and the basal lamina to aggravate BBB leakage ([@B47]). Conventional treatment for ICH includes respiratory support, management of both blood and intracranial pressures, anti-coagulation therapy, and surgical evacuation ([@B144]). The BBB serves as a trigger point for inflammatory cascades and, thus, participates in the whole ICH disease course. Considering this central role, advanced treatments have recently been developed that aim to modulate this immunoreaction to reduce secondary BBB injury of BBB ([Figure 3](#F3){ref-type="fig"}).

![Schematic diagram of blood-brain barrier changes in intracerebral hemorrhage. Perihematomal edema secondary to intracerebral hemorrhage can be divided into three phases. All the pathophysiological events result in degradation of tight-junction proteins, which exacerbate perihematomal edema and result in poor prognosis.](fnins-14-00764-g003){#F3}

Statins can alleviate PHE in ICH through anti-inflammatory mechanisms. [@B163] analyzed the use of statins in ICH patients and found that patients taking statins had better clinical outcomes. Likewise, celecoxib can inhibit inflammation and reduce brain edema through lowering prostaglandin E2 expression ([@B36]; [@B107]). The colony-stimulating factor 1 receptor inhibitor, PLX3397 depletes microglia, inhibits leukocyte infiltration and decreases the level of pro-inflammatory mediators, thereby eliminating BBB breakdown and brain edema ([@B108]). Transforming growth factor-β1 (TGF-β1) has also been shown to improve ICH prognosis through modulation of microglial phenotype and inhibition microglial-derived neuroinflammation ([@B183]). LRP-1 is able to obliterate hemoglobin, blocking subsequent damage and, thus, stabilizing the BBB in mice ([@B199]). Fingolimod, an immunomodulatory compound, has also been shown to protect the BBB and improve clinical sequelae through reducing MMP-9 expression, inhibiting infiltration of immune cells and secretion of inflammatory mediators ([@B148]; [@B111]). The peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, pioglitazone, is in phase II clinical trials to evaluate the safety of its application to promoting erythrocyte phagocytosis by microglia, which alleviates inflammation and protects the BBB *in vivo* (NCT00827892) ([@B59]). In addition, a randomized pilot phase II clinical trial of minocycline is also (NCT01805895) ([@B59]) assessing its BBB protection ability via reducing microglial infiltration and downregulating pro-inflammatory cytokine expression ([@B211]).

Neurodegenerative Disease {#S4}
=========================

Alzheimer's Disease {#S4.SS1}
-------------------

Alzheimer's disease is characterized by deposition of misfolded Aβ and tau proteins in the CNS parenchyma ([@B72]), leading to BBB breakdown and cognitive impairment ([@B124]; [@B91]). Autopsy studies on patients with confirmed AD showed that more than half of these patients had evident vascular alterations ([@B179]). Hereditary susceptibility combined with environmental factors, such as pollutants and diet, evoke a series of vascular changes. In fact, BBB disruption, as a contributor to the pathophysiological process, exists before the formation of typical vascular pathology. There is two-hit vascular hypothesis ([@B129]), in which vascular dysfunction plays a leading role in the initial stages, resulting in ischemia-hypoxia and EC injury, and then facilitates deposition of neurotoxic substances in the CNS during the second stage.

APOE genetic variants, among the greatest genetic risk factors for sporadic AD, have been shown to cause BBB disruption and degeneration of PCs ([@B195]; [@B71]). In APOE4 carriers with normal cognition or mild cognitive impairment (MCI), a prelude to AD, dynamic contrast-enhanced magnetic resonance imaging evidenced BBB leakage prior to tissue loss, indicating that BBB disruption is independent of Aβ and tau deposition ([@B87]; [@B125]). In addition, secreted PDGFRβ (sPDGFRβ), a biomarker of PC injury, is elevated in the cerebrospinal fluid (CSF) of APOE4 carriers ([@B87]; [@B125]) and has been shown to be independent of pathological changes in AD ([@B125]). Of all APOE isoforms, APOE4 increases AD susceptibility dramatically compared with APOE3, and APOE2 reduces AD risk ([@B195]). APOE4 activates cytokine cyclophilin A (CypA), nuclear factor-κB (NF-κB) and MMP-9 in both PCs and ECs, degrading TJ and BM proteins, downregulating GLUT1 expression and upregulating expression of RAGE ([@B126]). RAGE binds peptides and mediates influx of Aβ ([@B24]), thus damaging PCs and the BBB ([@B18]; [@B71]). The impact of APOE4 on ECs and PCs is independent of Aβ or tau elevation ([@B87]). Furthermore, increased APOE burden reduces Aβ transport, resulting in its accumulation in the brain and accelerating the course of the disease ([@B65]). Therefore, BBB dysfunction can independently trigger subsequent disorders and exacerbate cognitive impairment.

Moreover, evidence indicates that VSMCs and ECs can produce Aβ peptides in the adult brain ([@B96]; [@B159]). The BBB is also an underlying source of Aβ peptides, which downregulate ZO-1, occludin, and claudin-5 and increase the permeability of ECs through interaction with RAGE, activation of MMPs and stimulation of oxidative stress pathways ([@B26]; [@B99]). In addition, it has been shown that Aβ peptides promote angiogenesis and redistribution of TJs, impairing BBB integrity and allowing Aβ leakage ([@B21]).

The ABC superfamily is important for lipoprotein metabolism and Aβ efflux ([@B95]; [@B123]). *P*-gp and ABCG2 not only facilitate transport of Aβ across the BBB via LRP1 binding ([@B37]; [@B177]), but also restrict Aβ influx ([@B24]). ABCA1 mediates the transfer of cholesterol to APOE, high-density lipoprotein (HDL), and APOA-I and modifies the cleavage of amyloid precursor protein (APP) as well as clearance of Aβ across the BBB ([@B151]; [@B102]; [@B41]). ABCA7 is the only ABC transporter implicated by AD Genome Wide Association Studies (GWAS) ([@B79]). Absence of ABCA7 expression reduces the level of ABCA1 and APOE secretion with a concurrent reduction in cholesterol exchange (particularly that of HDL and ApoA-I) and Aβ efflux ([@B103]).

LRP-1 is the main transporter of Aβ with dysfunction increasing Aβ levels and promoting AD ([@B88]). *P*-gp, located on the luminal side of ECs, limits the transport of multiple products ([@B157]), including Aβ. *P*-gp deficiency contributes to LRP1 dysfunction and increases Aβ levels ([@B37]). A recent experiment involved in the BBB model *in vitro* indicated that a ketogenic diet could enhance expressions of LRP1, *P*-gp, and PICALM and, thus, promote Aβ efflux across the BBB ([@B196]). PICALM has been shown to promote binding of LRP1 to Aβ as well. It promotes Aβ endocytosis and Aβ-LRP1 transcytosis by transferring the protein complex to Rab5 and Rab11 ([@B220]). Furthermore, PICALM gene mutations have also been implicated in AD ([@B184]; [@B219]) ([Figure 4](#F4){ref-type="fig"}).

![Genetic mutations and Aβ production in the blood-brain barrier increase the risk of AD. Genetic mutations, such as ABCA7, PICALM, and APOE, lead to dysfunction of BBB transport systems, resulting in Aβ deposition in the brain. Aβ accumulation gives rise to blood-brain barrier breakdown and cognitive impairment, characteristic of Alzheimer's disease.](fnins-14-00764-g004){#F4}

Therapeutic BBB modulation has shown promising results in AD treatment. FPS-ZM1, an innoxious RAGE suppressant, inhibits RAGE activation and reduces entry of Aβ within the brain, thereby suppressing neuroinflammation ([@B51]). [@B191] found that inhibiting the mammalian/mechanistic target of the rapamycin (mTOR) pathway can maintain BBB integrity and restore cognitive function. [@B15] also succeeded in constructing a nanodevice to alter Aβ morphology and treat AD, which needs further clinical trials.

Parkinson's Disease {#S4.SS2}
-------------------

Parkinson's disease (PD) is a neurodegenerative disease characterized by tremors, limb rigidity, and hypokinesis ([@B23]). The main pathological hallmark of PD is the progressive death of dopaminergic neurons in the substantia nigra (SN) and deposition of Lewy bodies (LBs), fibrillar aggregates composed of α-synuclein (α-syn), leucine-rich repeat kinase 2 (LRRK2), and other proteins ([@B105]; [@B198]). PD occurrence is influenced by hereditary susceptibility, environmental toxins (such as rotenone and pesticides), age-related neurodegeneration, and interactions between these factors.

BBB lesions, including a thickened BM and degraded PCs, have been observed in PD ([@B57]). Additionally, prominent BBB leakage has been shown in the striatum of PD patients with deposition of fibrin and hemosiderin forecasting its vulnerability ([@B67]). Positive correlations have also been found between parenchymal iron levels, resulting from BBB leakage, and brain pathology in PD patients ([@B66]). In addition to iron, extravasation of red blood cells that act as a source of α-syn might also contribute to PD pathology ([@B181]). Degradation of TJ proteins cause BBB injury and enhanced transcytosis. A recent study showed that misfolded α-syn could downregulate ZO-1 and occludin expression, indicating that α-syn is neurotoxic to the BBB ([@B101]). Degradation of ECs also generates BBB breakdown and initiates neurodegenerative pathology. In addition, decreased expression of GLUT-1 and ABCG2 were evident in PD mouse models, and P-gp expression was increased ([@B192]; [@B155]). However, another study has found a reduction in *P*-gp expression although this could be attributed to the methods of establishing the models ([@B80]; [@B134]). *P*-gp dysfunction also plays an important role in PD pathogenesis due to decreased clearance of neurotoxic substances ([@B100]), leading to their accumulation in the BBB, similarly to its role in AD pathogenesis. Thus, P-gp could be a promising therapeutic target in PD as well. Despite clearly thickened BM and decreased *P*-gp function in PD ([@B134]), the specific pathological mechanisms remain unclear. Neuroinflammation likely also plays a crucial role in this process with α-syn transport or iron deposition initiating the inflammatory reaction. It has been shown that metabolic iron disorders induce oxidative stress and free radical production, resulting in the induction of neurotoxic cascades ([@B38]; [@B204]). Activated microglia secrete inflammatory factors, upregulate EC expression of adhesion molecules and recruit leukocytes, and amplify inflammatory cascades, ultimately resulting in neuronal ([@B145]). Inflammatory cytokines also downregulate ZO-1 and occludin, thus increasing BBB permeability ([@B209]). The inflammatory mediators MMP-3 and nuclear factor erythroid 2--related factor 2 (NRF2) have been show to stimulate α-Syn production, induce aggregation of amyloidogenic compounds and induce the release of inflammatory cytokines, mediating death of dopaminergic neurons ([@B147]; [@B167]). Interestingly, knockout of TNF-α expression in PD model mice attenuated BBB leakage ([@B218]).

Furthermore, CSF from PD patients contains elevated levels of angiogenesis factors ([@B90]). Aberrant angiogenesis results in generation of immature vasculature and loose intercellular junctions, which has been connected with dopaminergic neuronal loss through leakage of neurotoxic substances ([@B52]). To summarize, BBB injury leads to substantial leakage of peripheral substances, thus expediting development of neurodegenerative disorders.

There are now multiple advanced treatments and newfound targets for PD. Milk fat globule-epidermal growth factor-VIII (MFG-E8) can promote neurogenesis and restore impaired neurocytes in PD ([@B34]). Statins exert neuroprotective effects in PD models through anti-inflammatory and anti-oxidation mechanisms, providing a promising treatment option ([@B149]; [@B210]). Glutathione is an antioxidative agent and demonstrates beneficial effects in PD by protecting dopaminergic neurons ([@B170]). Anti-complement agents that regulate immunoreactivity through inhibition of complement pathways have been effective in PD models but require further verification in clinical trials ([@B25]). Increased expression of hepcidin accelerates iron transport and metabolism, thus providing an additional potential therapy ([@B143]). Iron-chelation therapy is beneficial for adjusting iron homeostasis ([@B204]). Glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) are all beneficial for neural revival and regeneration, thus transporting these factors across the BBB could be an option for PD treatment ([@B3]). Several options are available for improved delivery of therapeutics across the BBB, including using micro- or nanotechnology to bind therapeutic agents or delivery of small hydrophobic agents with liposomal targeting ([@B186]; [@B202]). Focused ultrasound (FUS) to open specific BBB regions and facilitate entry of therapeutic compounds is currently in phase 1 trials for PD treatment (NCT03608553) ([@B221]).

Multiple Sclerosis {#S4.SS3}
------------------

Multiple sclerosis (MS) is characterized by remitting-relapsing demyelination and axon loss. It is a chronic and progressive CNS inflammatory disorder, which ultimately evolves over time into neurodegeneration ([@B75]). The use of gadolinium enhancement in MRI has allowed measurement of BBB breakdown in MS ([@B122]), which is deemed as a trigger point for disease onset; the presence of immunocytes in the immune-privileged brain parenchyma via BBB breakdown induces the autoimmune disease in a hereditarily susceptible population ([@B42]).

Energy metabolism dysfunction and endocrine disorders have been shown to initiate MS through crosstalk with immune cells ([@B142]; [@B49]). In addition, viral infection and environmental toxins in hereditarily susceptible individuals have also been shown to reduce immune tolerance and stimulate release of proinflammatory factors, such as IL-6 and NF-κB. As previously mentioned, these proinflammatory factors promote alternation of TJs and damage BBB integrity ([@B205]) as well as facilitate leukocyte transmigration ([@B160]). *P*-gp expression is also increased and enhances migration of CD4^+^ and CD8^+^ T cells to further amplify neuroinflammation ([@B98]). Silencing of P-gp expression significantly reduces CD8^+^ T cell trafficking into the CNS ([@B98]). Under inflammatory conditions, EC expression of selectins and their corresponding ligands are also elevated, promoting leukocyte binding; this mediates further interaction between integrins and their ligands, thus strengthening the adherence of leukocytes ([@B206]). Further to this, cytokines and chemokines upregulate endothelial adhesion receptors, including PECAM1, *E*-selectin, VCAM, and ICAM-1 and augment subsequent leukocyte infiltration ([@B146]). PECAM-1 facilitates leukocyte adherence and directs para-endothelial infiltration, thereby contributing to increased inflammation ([@B146]; [@B116]). VCAM upregulates the expression of integrin α-4 in ECs, reducing the level of TJ proteins ([@B69]). Integrin α-4 is also indispensable for CD8 + T lymphocyte recruitment ([@B83]). ICAM-1 plays a crucial role in inflammation through phosphorylation of TJ proteins and restructuring of the cytoskeleton, thus promoting increased BBB permeability ([@B82]). Both VCAM and ICAM mediate trans-endothelial infiltration of leukocytes ([@B78]). CD4^+^ T cells identify myelin sheath proteins and macrophages, and upregulate the release of pro-inflammatory factors (including IFN-γ, TNF-α, nitric oxide and free radicals), thus leading to demyelination ([@B78]). Neutrophils, monocytes, and microglia infiltrate the brain parenchyma and release extracellular glutamate, generating excitotoxity and accelerating BBB dysfunction ([@B118]). Furthermore, fibrinogen leakage from the BBB prompts release of ROS by microglia ([@B48]). Accumulation of leukocytes in the parenchyma induces further release of ROS, resulting in demyelination and breakdown of TJ proteins ([@B189]; [@B76]). Demyelinated lesions further induce secretion of free radicals, magnifying the inflammatory reaction ([@B12]). As a result, the excessive oxidative stress downregulates occludin and ZO-1, thus further promoting TJ disruption ([@B132]).

Other members of the NVU also disrupt BBB integrity. In pathological circumstances, the AQP4-mediated polarization of ACs becomes misregulated, resulting in retraction of end-feet from the glia limitans ([@B208]; [@B172]). Moreover, AC-expressed VEGF-A activates the downstream factor, *e*-nitrogen oxide (eNOS), which disrupts EC expression of claudin-5 and occludin and disrupts the BBB ([@B6]). Oligodendrocyte precursor cells (OPCs) also accumulate in MS lesions, interrupting AC end-feet contacts and TJ integrity as well as impairing lesion repair and altering BBB permeability ([@B130]). To summarize, immune system abnormalities induce alterations in BBB TJs, which facilitates trans-endothelial migration of leukocytes and ultimately leads to neurodegeneration ([@B160]).

Disease-modifying therapies (DMTs) are a basic therapy for MS with multiple advanced drugs developed and clinically tested. Ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, was approved for MS treatment in March 2020 ([@B104]). Siponimod is undergoing a phase-3 trial (NCT01185821) due to its beneficial effects on relapsing-remitting MS ([@B93]). Ibudilast is currently in phase-2 trials due to its capability of crossing the BBB and restricting the shift in macrophage phenotype, thus benefiting progressive MS (NCT01982942) ([@B58]). Immunoablation and autologous hemopoietic stem-cell transplantation (aHSCT) has passed a phase 2 single-arm trial, which aims to provide long-term control of aggressive MS (NCT01099930) ([@B10]). Minocycline has also been verified in clinical trials to lower the risk of clinically isolated syndromes progressing into MS (NCT00666887) ([@B121]). As previously stated, application of nanomaterials is an efficient way to deliver agents across the BBB ([@B61]). Fingolimod reduces monocyte migration and reverses BBB dysfunction through targeting ACs ([@B190]). However, a recent large comparative study found that patients treated with fingolimod have a higher risk of cancer due to increased tumorigenicity from immunosuppression; use of rituximab and natalizumab in MS do not elevate invasive cancer risk ([@B4]). Natalizumab, a monoclonal antibody (McAb) mainly used in treatment of relapsing-remitting MS, can prevent leukocyte adherence and blocks integrin α-4 on ECs, thereby protecting the BBB ([@B69]). However, as an efficient inflammatory suppressant, it also inhibits immune surveillance and leads to progressive multifocal leukoencephalopathy (PML), an infectious disease caused by John Cunningham virus ([@B141]), which unfortunately restricts its clinical application.

Conclusion {#S5}
==========

In summary, BBB disruption plays a central role in the pathophysiology of cerebrovascular and neurodegenerative disease. Dysfunction in energy metabolism and leakage of blood components catalyze CNS inflammation in cerebrovascular disease. Conversely, in neurodegenerative disease, endogenous inflammation is stimulated when genetically susceptible individuals develop endocrine disorders or are exposed to environmental factors, such as pollutants and exogenous infection. Despite diverging induction mechanisms, inflammation is a common characteristic of these CNS diseases. In general, disruption of the homeostatic CNS microenvironment triggers BBB reconstruction, resulting in leukocyte infiltration and leakage of neurotoxic substances that augment further neuroinflammation, which, in turn, exacerbates BBB permeability. Therefore, preservation of the BBB is a crucial therapeutic target. Recent investments mainly focus on the following two aspects: modulation of the inflammatory cascade modulation (including NOS, ROS, cytokines and chemokines) and BBB reinforcement. In this review, we have first correlated pro-inflammatory mediators with changes in the corresponding BBB-expressed molecules and listed several recent advanced treatments targeting the BBB and the inflammatory response. Existing therapies are also being applied to limit severe BBB dysfunction and the inflammation cascade. Further studies should concentrate on limiting the initial inflammation prior to BBB remodeling and on consolidating BBB integrity by directly promoting the synthesis of relevant TJ proteins; this may significantly improve treatment efficacy. In a word, BBB dysfunction is more of a contributor to CNS pathology than a victim in neurological disorders, and so more attention should be paid to its significant function in maintaining CNS homeostasis.
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